Pulmonary fibrolysis in a patient with idiopathic pulmonary fibrosis: improvement of clinical and radiological pattern after treatment with pirfenidone

被引:3
|
作者
Varone, Francesco [1 ]
Mastrobattista, Annelisa [1 ]
Franchi, Paola [2 ]
Viglietta, Luca [1 ]
Poletti, Venerino [3 ,4 ]
Tomassetti, Sara [3 ]
Dubini, Alessandra [5 ]
Tagliaboschi, Linda [1 ]
Calandriello, Lucio [2 ]
Farchione, Alessandra [2 ]
Larici, Anna Rita [2 ]
机构
[1] Catholic Univ, A Gemelli Hosp, Cardiothorac Dept, Pulmonol Unit, Rome, Italy
[2] Catholic Univ, A Gemelli Hosp, Inst Radiol, Dept Bioimaging & Radiol Sci, Rome, Italy
[3] GB Morgagni L Pierantoni Hosp, Dept Dis Thorax, Forli, Italy
[4] Aarhus Univ Hosp, Dept Resp Dis & Allergol, Aarhus, Denmark
[5] GB Morgagni L Pierantoni Hosp, Pathol Unit, Forli, Italy
关键词
idiopathic pulmonary fibrosis; high-resolution computed tomography; honeycombing; multidisciplinary team; pirfenidone; DIAGNOSIS;
D O I
10.1111/crj.12515
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive, fibrosing interstitial pneumonia associated with the histologic and/or radiologic pattern of usual interstitial pneumonia (UIP). Nowadays, the high-resolution computed tomography pattern of definite UIP is enough to define a diagnosis of UIP without histological proof. This is pivotal especially in elderly patients with comorbidities. Early recognition of IPF is relevant for its prognostic implication. Some pharmacological strategies have been proposing novel molecules that tend to slow lung function decline, even though without healing fibrosis. We report a case of ex-heavy smoker male with IPF showing clinical and radiological improvement after 11 months of treatment with Pirfenidone. The definite diagnosis was challenging and it was reached by a multidisciplinary approach.
引用
收藏
页码:347 / 351
页数:5
相关论文
共 50 条
  • [1] Marked Improvement with Pirfenidone in a Patient with Idiopathic Pulmonary Fibrosis
    Miyamoto, Atsushi
    Morokawa, Nasa
    Takahashi, Yui
    Ogawa, Kazumasa
    Takeyasu, Makiko
    Murase, Kyoko
    Hanada, Shigeo
    Uruga, Hironori
    Mochizuki, Sayaka
    Takaya, Hisashi
    Kurosaki, Atsuko
    Kishi, Kazuma
    INTERNAL MEDICINE, 2016, 55 (06) : 657 - 661
  • [2] Pirfenidone for the treatment of idiopathic pulmonary fibrosis
    Xaubet, Antoni
    Serrano-Mollar, Anna
    Ancochea, Julio
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (02) : 275 - 281
  • [3] Pirfenidone treatment of idiopathic pulmonary fibrosis
    Azuma, Arata
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2012, 6 (02) : 107 - 114
  • [4] Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis
    Bonella, F.
    Wessendorf, T. E.
    Costabel, U.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2013, 138 (11) : 518 - 523
  • [5] Remarkable Improvement in a Patient with Idiopathic Pulmonary Fibrosis after Treatment with Nintedanib
    Nakano, Akiko
    Ohkubo, Hirotsugu
    Fukumitsu, Kensuke
    Fukuda, Satoshi
    Kanemitsu, Yoshihiro
    Takemura, Masaya
    Maeno, Ken
    Ito, Yutaka
    Oguri, Tetsuya
    Niimi, Akio
    INTERNAL MEDICINE, 2019, 58 (08) : 1141 - 1144
  • [6] Pirfenidone for the treatment of idiopathic pulmonary fibrosis
    George, Peter M.
    Wells, Athol U.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (05) : 483 - 491
  • [7] Pirfenidone for the treatment of idiopathic pulmonary fibrosis
    Poletti, Venerino
    Ravaglia, Claudia
    Tomassetti, Sara
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2014, 8 (05) : 539 - 545
  • [8] Pirfenidone and Nintedanib for Treatment of Idiopathic Pulmonary Fibrosis
    Sathiyamoorthy, Gayathri
    Sehgal, Sameep
    Ashton, Rendell W.
    SOUTHERN MEDICAL JOURNAL, 2017, 110 (06) : 393 - 398
  • [9] Genetic variations in idiopathic pulmonary fibrosis and patient response to pirfenidone
    Kubbara, Aahd
    Amundson, William H.
    Herman, Adam
    Lee, Adam M.
    Bishop, Jeffrey R.
    Kim, Hyun Joo
    HELIYON, 2023, 9 (08)
  • [10] Pirfenidone treatment of idiopathic pulmonary fibrosis
    Gan, Ye
    Herzog, Erica L.
    Gomer, Richard H.
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2011, 7 : 39 - 47